Search Medical Condition
Please enter condition
Please choose location from dropdown

Immenstadt, Germany Clinical Trials

A listing of Immenstadt, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (11) clinical trials

Tack Optimized Drug Coated Balloon Angioplasty Study of the Tack Endovascular System in Femoropoliteal Arteries

This is an Outside the United States, post-CE Mark, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System. This study will evaluate subjects with PAD who receive PTA (with a drug-coated balloon (DCB)) in the SFA and in popliteal arteries, ranging in diameter ...

Phase N/A

0.0 miles

Learn More »

Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions

Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter in the treatment of de novo or restenotic lesions in the superficial femoral and/or popliteal arteries Cohort 2: To evaluate this patient population for treatment of in-stent restenotic ...

Phase N/A

0.0 miles

Learn More »

A Trial With Metronomic Low-dose Treosulfan Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC

Patients will be randomized 1:1, and will be stratified according to histology (squamous cell carcinoma vs adenocarcinoma). 86 patients with platin refractory Non-Small Cell Lung Cancer (NSCLC) will be treated either with metronomic low-dose treosulfan, pioglitazone and clarithromycin (experimental arm) or with nivolumab (squamous cell lung cancer and nonsquamous cell ...

Phase

0.0 miles

Learn More »

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

The primary objective is to investigate efficacy of a nivolumab-radiotherapy combination treatment in metastatic non-squamous NSCLC patients.

Phase

0.0 miles

Learn More »

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).

Phase

2.12 miles

Learn More »

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment nave and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Phase

2.12 miles

Learn More »

An Investigational Immuno-therapy Trial of Nivolumab or Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum-doublet Chemotherapy Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

Phase

2.12 miles

Learn More »

Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING

Interstitial lung diseases (ILD) are a heterogeneous group of more than 200 entities that can be idiopathic or as a result of other diseases and/or treatments. All forms of ILD are considered to be seldom or very seldom (and most of them are so-called "orphan" diseases), in their entirety they ...

Phase N/A

2.12 miles

Learn More »

Absorb IV Randomized Controlled Trial

ABSORB IV: A. Primary Objective: - To evaluate 1-year clinical outcomes of the Absorb BVS compared to XIENCE in the treatment of subjects with ischemic heart disease caused by up to three de novo native coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two ...

Phase N/A

2.12 miles

Learn More »

RECCORD (Recording Courses of Vascular Diseases) Registry

For details see NM Malyar et al., Rationale and design of the RECording COurses of vasculaR Diseases registry (RECCORD registry). Vasa. https://doi.org/10.1024/0301-1526/a000631

Phase N/A

2.12 miles

Learn More »